• Recursion Pharmaceuticals director Robert Hershberg exercised stock options for 25,000 Class A shares at USD 2.22 on Oct. 6, 2026.
• He sold 25,000 Class A shares at USD 5 on the same day.
• Directly held Class A shares fell to 162,156 following the transactions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Recursion Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001601830-26-000119), on October 07, 2026, and is solely responsible for the information contained therein.